Table 2.
Characteristics and modeling insights from the eligible studies
| Study, country (cost year; currencya) | Perspective | Evaluation type | Comparator type | Model type | Max. time horizon (years) | Discounting (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P | S | O | CEA | CUA | TM | LT | SI | MIGS | D/S | MK | DT | MS | NA/O | Costs | HO | ||
|
Ordóñez et al. [20] Colombia (2017; USD) |
x | x | x | x | x | x | Life | 5.0 | 5.0 | ||||||||
|
CADTH [23] Canada (2016; CAD) |
x | x | x | x | Life | 1.5 | 1.5 | ||||||||||
|
John and Parikh [8] India (2016; INR) |
x | x | x | x | 10 | 3.0 | 3.0 | ||||||||||
|
John and Parikh [9] India (2015; INR) |
x | x | x | x | 10 | 3.0 | 3.0 | ||||||||||
|
Paletta Guedes et al. [5] Brazil (2014; BRL) |
x | x | x | x | x | x | x | Life | 5.0 | 5.0 | |||||||
|
Boodhna and Crabb [13] UK (2015; GBP) |
x | x | x | x | 25 | NA | NA | ||||||||||
|
Kaplan et al. [19] USA (2013; USD) |
x | x | x | x | 5 | 3.0 | 3.0 | ||||||||||
|
Orme et al. [15] UK (2008–09; GBP) |
x | x | x | x | 10 | 3.5 | 3.5 | ||||||||||
|
Stein et al. [17] USA (2010; USD) |
x | x | x | x | x | x | 25 | 3.5 | NA | ||||||||
|
van Gestel et al. [14] Netherlands (2006; EUR) |
x | x | x | x | x | Life | 4 | 1.5 | |||||||||
|
Paletta Guedes et al. [18] Brazil (2010; BRL) |
x | x | x | x | 5 | 3 | NA | ||||||||||
|
Wittenborn and Rein [10] Barbados, Ghana (2005; USD) |
x | x | x | x | Life | 3 | 3 | ||||||||||
|
Rein et al. [24] USA (2005; USD) |
x | x | x | x | x | Life | 3 | 3 | |||||||||
|
Stewart et al. [16]; NOR, SWE, DEN, UK (2005; USD) |
x | x | x | x | 5 | NA | NA | ||||||||||
|
Hernández et al. [12] UK (2006; GBP) |
x | x | x | x | Life | 3.5 | NA | ||||||||||
|
Peeters et al. [25] Netherlands (2001; EUR) |
x | x | x | x | 20 | 4 | 4 | ||||||||||
|
Payet et al. [26] France (2005; EUR) |
x | x | x | x | 5 | 3.5 | NA | ||||||||||
|
Vaahtoranta-Lehtonen et al. [11] Finland (2003; EUR) |
x | x | x | x | x | 20 | 5 | 5 | |||||||||
|
Bernard et al. [27] France (2002; EUR) |
x | x | x | x | 3 | 3 | 0 | ||||||||||
|
Eandi et al. [28] Italy (1998–99; ITL) |
x | x | x | x | NA | NA | NA | ||||||||||
|
Rochi and Tingey [29] Canada (1996; CAD) |
x | x | x | x | 10 | 5 | 5 | ||||||||||
|
Gottlieb et al. [30] USA (1980; USD) |
x | x | x | x | NA | 5 | 5 | ||||||||||
CEA cost-effectiveness analysis, CUA cost-utility analysis, DEN Denmark, D/S diagnosis/screening, DT decision tree, LT laser trabeculoplasty, HO health outcomes, max maximum, MIGS minimally invasive glaucoma surgery, MK Markov, MS microsimulation, NA not available, NOR Norway, O other, P payer, S societal, SI surgical intervention, SWE Sweden, TM topical medications, y years
aCurrency is listed as per the International Organization for Standardization code